Topics & People

Generic versions of biologic drugs. The FDA is cutting the red tape for their approval to increase competition and lower drug prices.

A class of expensive medications manufactured using a cell line. The FDA is working to lower their prices by accelerating the approval of their generic equivalents, biosimilars.

A policy pursued by the Trump administration to ensure the US pays the lowest price for pharmaceuticals among developed nations, aiming to radically lower drug costs.

Centers for Disease Control and Prevention.

A new, smaller, and prioritized list of recommended childhood vaccines (38 doses) created by the FDA to rebuild public trust and combat vaccine hesitancy.

A physiological condition, often driven by high carbohydrate intake, that is at the root of most chronic diseases like diabetes and heart disease.

A major public health crisis in the United States, with 40-60% of the adult population being clinically obese. It's being addressed by both dietary changes and new drugs like GLP-1s.

A class of food products that have been stripped of fiber and nutrients, identified as a primary driver of the obesity and diabetes epidemics in American children.

The scientific field related to diet and health, which Marty Makary describes as one of the most corrupted fields, leading to flawed dietary guidance like the old Food Pyramid.

A law, signed by President Trump, that allows patients with life-threatening diseases to access experimental treatments that have not yet received full FDA approval.

The practice of monitoring the safety and efficacy of drugs after they have been approved and are in public use, which the FDA plans to enhance using big data and AI.

A proposed new paradigm for clinical research where data is monitored in real-time, rather than in discrete phases, to accelerate the drug development process.